Table 1.
Clinical characteristics, PLM and ferritin levels in patients with NT1 with and without RLS.
| Variable |
NT1 without RLS N = 46 |
NT1 with RLS N = 20 |
P | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Gender, women | 15 | 32.61 | 7 | 35.00 | 0.85 |
| Age, years 1 | 39.00 (14.00; 80.00) | 35.50 (15.00; 81.00) | 0.46 | ||
| BMI, kg/m2 1 | 27.34 (19.49; 37.11) | 25.67 (18.73; 34.61) | 0.34 | ||
| Hypnagogic/hypnopompic hallucinations, yes | 32 | 74.42 | 16 | 80.00 | 0.63 |
| Sleep paralysis, yes | 25 | 58.14 | 13 | 65.00 | 0.60 |
| Duration of evolution of NT1, years 1 | 10.00 (1.00; 64.00) | 5.00 (1.00; 69.00) | 0.72 | ||
| CSF ORX‐A levels, pg/mL 1 | 10.50 (0.00; 101.00) | 6.00 (0.00; 82.00) | 0.42 | ||
| PLM indexes | |||||
| Index PLMS, /h 1 | 4.20 (0.00; 39.57) | 3.24 (0.00; 161.90) | 0.21 | ||
| Index PLMS ≥15/h | 12 | 26.09 | 6 | 30.00 | 0.74 |
| Index PLMS associated with MA, /h 1 | 1.30 (0.00; 21.23) | 1.00 (0.00; 50.70) | 0.24 | ||
| Index of PLMS associated with MA ≥15/h | 1 | 2.27 | 1 | 5.26 | 0.55 |
| Index PLM wake, /h 1 | 11.60 (0.00; 85.60) | 9.57 (0.00; 105.60) | 0.32 | ||
| Index PLM wake ≥15/h | 17 | 37.78 | 8 | 42.11 | 0.75 |
| Ferritin levels | |||||
| Ser‐Ferr, ng/mL 1 | 102.00 (12.00; 500.00) | 95.00 (15.00; 281.00) | 0.14 | ||
| Ser‐Ferr, ng/mL ≤50 | 6 | 13.95 | 6 | 30.00 | 0.14 |
| Ser‐Ferr, ng/mL ≤75 | 12 | 27.91 | 9 | 45.00 | 0.18 |
| CSF‐Ferr, ng/mL 1 | 6.82 (3.07; 14.89) | 5.82 (3.00; 11.80) | 0.27 | ||
| CSF‐Ferr, ng/mL 2 | |||||
| <5.47 | 13 | 28.26 | 8 | 40.00 | 0.64 |
| [5.47–7.73] | 16 | 34.78 | 6 | 30.00 | |
| ≥7.73 | 17 | 36.96 | 6 | 30.00 | |
BMI, body mass index; CSF, cerebrospinal fluid; CSF‐Ferr, CSF ferritin levels; MA, microarousal; NT1, narcolepsy type 1; ORX‐A, orexin‐A levels; PLM, periodic leg movements; PLMS, periodic leg movements during sleep; RLS, restless legs syndrome; Ser‐Ferr, serum ferritin levels.
1
Continuous variables are expressed as median (minimal value; maximal value).
2
Tertiles of the NT1 sample (n = 66).